{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:09:34Z","timestamp":1787242174478,"version":"build-2736575974"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Docetaxel has been a standard treatment for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Cabazitaxel, a related taxane, was approved in 2010 for patients with mCRPC who had been previously treated with docetaxel. The comparative effectiveness of docetaxel rechallenge vs switching to cabazitaxel after prior docetaxel for mCRPC remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the clinical outcomes associated with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel in the mCRPC setting.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study was conducted in the nationwide Veterans Affairs health care system, using inverse probability of treatment weighting to control for potential confounders. Patients who were diagnosed with chemonaive mCRPC between January 1, 2010, and December 31, 2023, received initial docetaxel treatment, and did not experience disease progression were eligible to participate.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Treatment with docetaxel rechallenge or cabazitaxel.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was overall survival (OS) from the initiation of the second course of taxane, which was compared in patients treated with docetaxel rechallenge vs cabazitaxel using weighted Kaplan-Meier analysis and Cox proportional hazards regression models. Secondary outcomes included prostate-specific antigen response, time to next systemic treatment or death, and subsequent treatments received.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 669 patients (407 receiving cabazitaxel and 262 receiving docetaxel rechallenge) with a median age of 72 (IQR, 67-77) years were included. Patients treated with docetaxel rechallenge had a significantly longer OS (median, 12.3 [IQR, 10.5-13.8] months) compared with those treated with cabazitaxel (median, 9.6 [IQR, 8.6-11.1] months), with a hazard ratio of 0.81 (95% CI,\u20090.55-0.99;\n P<\/jats:italic>\n \u2009=\u2009.04). Descriptive analysis of secondary outcomes was consistent with this finding, including prostate-specific antigen response (weighted 9.8% achieving reduction of 90% or more in the docetaxel rechallenge group vs 3.0% in the cabazitaxel group) and time to next treatment or death (median, 10.7 [IQR, 7.8-12.7] months in the docetaxel rechallenge group vs 8.9 [IQR, 7.1-10.5 months] in the cabazitaxel group). Use of platinum, immunotherapy, or poly (ADP-ribose) polymerase inhibitors was similar between patients treated with cabazitaxel and docetaxel rechallenge.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with mCRPC, docetaxel rechallenge was associated with improved OS compared with cabazitaxel among patients who did not experience disease progression during prior docetaxel for mCRPC. These findings support docetaxel rechallenge as a treatment option for patients in this scenario.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.51231","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:30:40Z","timestamp":1768581040000},"page":"e2551231","source":"Crossref","is-referenced-by-count":2,"title":["Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Pedro C.","family":"Barata","sequence":"first","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June K.","family":"Corrigan","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"La","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Culnan","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Akama-Garren","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlynn N.","family":"Dulberger","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Dumontier","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hansen","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, University of New England, Biddeford, Maine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Bihn","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda L.","family":"Bitting","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs (VA) Medical Center, Durham, North Carolina"},{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Washington, Seattle"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[{"name":"Surgical Service, San Francisco VA Medical Center (VAMC), San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Tito","family":"Fojo","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University and James J. Peters VAMC, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Gaziano","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey D.","family":"Goryachev","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Hauger","sequence":"additional","affiliation":[{"name":"Research Service, Department of Veterans Affairs San Diego Healthcare System, San Diego, California"},{"name":"Center for Behavior Genetics of Aging, School of Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Rebbeck","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Cambridge, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Xian","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[{"name":"John J. Cohran Veterans Hospital, VA St Louis Healthcare System, St Louis, Missouri"},{"name":"Department of Medicine, St Louis University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin N.","family":"Swinnerton","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenute","family":"Myrie","sequence":"additional","affiliation":[{"name":"Office of Research and Development, Veterans Health Administration, US Department of Veterans Affairs, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Ramoni","sequence":"additional","affiliation":[{"name":"Office of Research and Development, Veterans Health Administration, US Department of Veterans Affairs, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center, Department of Veterans Affairs Healthcare System, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California"},{"name":"Prostate Cancer Program of the Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"41","key":"zoi251361r1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001-2017.","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"zoi251361r2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, Version 4.2023, NCCN clinical practice guidelines in oncology.","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"zoi251361r3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1200\/JCO.2025.43.5_suppl.59","article-title":"Real-world treatment patterns and outcomes in advanced prostate cancer: a cohort study using the prostate cancer disease observation (PRECISION) data platform.","volume":"43","author":"Heath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi251361r4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi251361r5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi251361r6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s11255-018-1963-1","article-title":"Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.","volume":"50","author":"Thomas","year":"2018","journal-title":"Int Urol Nephrol"},{"issue":"14","key":"zoi251361r7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002754","article-title":"Docetaxel rechallenge in a heavily pretreated patient with castration-resistant prostate cancer: a case report and review of literature.","volume":"95","author":"Di Lorenzo","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"9747","key":"zoi251361r8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"zoi251361r9","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer.","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"28","key":"zoi251361r10","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA.","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"zoi251361r12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/CCI.21.00030","article-title":"Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing.","volume":"5","author":"Alba","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"zoi251361r13","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00085","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer.","volume":"7","author":"Candelieri-Surette","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"zoi251361r14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs.","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"issue":"8","key":"zoi251361r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28444","article-title":"Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer.","volume":"7","author":"La","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zoi251361r16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi251361r17","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi251361r18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9747","key":"zoi251361r19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"zoi251361r20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi251361r21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/gerona\/glab071","article-title":"Updating and validating the US Veterans Affairs Frailty Index: transitioning from ICD-9 to ICD-10.","volume":"76","author":"Cheng","year":"2021","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"zoi251361r22","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1111\/jgs.18540","article-title":"Construct validity of the electronic Veterans Affairs Frailty Index against clinician frailty assessment.","volume":"71","author":"DuMontier","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"zoi251361r23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/bjc.2016.251","article-title":"Loss of SLCO1B3 drives taxane resistance in prostate cancer.","volume":"115","author":"de Morr\u00e9e","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi251361r24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","article-title":"Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer.","volume":"4","author":"Pollard","year":"2017","journal-title":"Asian J Urol"},{"issue":"10","key":"zoi251361r25","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"zoi251361r26","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1002\/cncr.31355","article-title":"Cost considerations for systemic therapy for patients with advanced genitourinary malignancies.","volume":"124","author":"Henry","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"zoi251361r27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2021.10.016","article-title":"Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial.","volume":"81","author":"Baciarello","year":"2022","journal-title":"Eur Urol"},{"key":"zoi251361r11","unstructured":"Pharmaceutical prices. Office of Procurement, Acquisition and Logistics. Updated November 3, 2025. Accessed July 13, 2025. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2844039\/barata_2026_oi_251361_1767982496.3179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:30:41Z","timestamp":1768581041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2844039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.51231","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}